medicines
Focus on the Global South | 1-Jun-2017
In the recent “RCEP 18th Round of Talks,” members of civil society organizations and social movements presented their positions vis-à-vis the RCEP.
Inquirer.net | 18-May-2017
RCEP negotiations have been highly conspiratorial and undemocratic, with all 18 rounds of trade discussions held in secret and no reports shared with the public
People Over Profit | 12-May-2017
#NoRCEP week of actions at the 18th TNC Meeting of the Regional Comprehensive Economic Partnership
Forum on FTAs | 8-May-2017
RCEP magnifies existing inequalities and discriminates against women, indigenous peoples, people living with HIV or other illnesses, people with disabilities,rural communities, farmers and workers
keywords:
actions | resistance ,
India ,
investor-state disputes | ISDS ,
medicines ,
Philippines ,
RCEP ,
women
AFTINET | 3-May-2017
ISDS is increasingly being used by global corporations to challenge health, environment and other public interest laws.
Forum against FTAs | 27-Apr-2017
Trade unions, farmers groups, health activists, and other people’s movements are planning to organise a series of events to put pressure on the Government of India to withdraw from RCEP negotiations.
AGEFI | 13-Apr-2017
Le géant bâlois est accusé d’avoir "menacé" le ministère colombien du Commerce et de l’Industrie de recourir à un tribunal d’arbitrage international.
keywords:
Colombia ,
intellectual property ,
investor-state disputes | ISDS ,
medicines ,
Switzerland
Public Eye | 12-Apr-2017
Confidential documents obtained by Public Eye show that Novartis has threatened Colombia with international investment arbitration under its BIT with Switzerland to avoid the issuance of a compulsory license
keywords:
Colombia ,
corporate interests ,
intellectual property ,
investor-state disputes | ISDS ,
leaks ,
medicines ,
Switzerland
IA Reporter | 5-Apr-2017
Ukraine has settled a dispute with American pharmaceutical company Gilead Sciences Inc., following the company’s pursuit of legal remedies in both domestic courts and via investment arbitration.
Lexology | 27-Mar-2017
The Tribunal found that Eli Lilly had failed to demonstrate that the promise doctrine constitutes a fundamental or dramatic change in the utility requirement under Canadian patent law or that the promise doctrine is arbitrary and/or discriminatory.
keywords:
Canada ,
intellectual property ,
investor-state disputes | ISDS ,
medicines ,
NAFTA | USMCA ,
US
